Cargando…
Analysis of DNM3 and VAMP4 as genetic modifiers of LRRK2 Parkinson’s disease
The LRRK2 gene has rare (p.G2019S) and common risk variants for Parkinson’s disease (PD). DNM3 has previously been reported as a genetic modifier of the age at onset in PD patients carrying the LRRK2 p.G2019S mutation. We analyzed this effect in a new cohort of LRRK2 p.G2019S heterozygotes (n = 724)...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7762821/ https://www.ncbi.nlm.nih.gov/pubmed/32873436 http://dx.doi.org/10.1016/j.neurobiolaging.2020.07.002 |
_version_ | 1783627890390204416 |
---|---|
author | Brown, Emmeline E. Blauwendraat, Cornelis Trinh, Joanne Rizig, Mie Nalls, Mike A. Leveille, Etienne Ruskey, Jennifer A. Jonvik, Hallgeir Tan, Manuela M.X. Bandres-Ciga, Sara Hassin-Baer, Sharon Brockmann, Kathrin Infante, Jon Tolosa, Eduardo Ezquerra, Mario Ben Romdhan, Sawssan Benmahdjoub, Mustapha Arezki, Mohamed Mhiri, Chokri Hardy, John Singleton, Andrew B. Alcalay, Roy N. Gasser, Thomas Grosset, Donald G. Williams, Nigel M. Pittman, Alan Gan-Or, Ziv Fernandez-Santiago, Ruben Brice, Alexis Lesage, Suzanne Farrer, Matthew Wood, Nicholas Morris, Huw R. |
author_facet | Brown, Emmeline E. Blauwendraat, Cornelis Trinh, Joanne Rizig, Mie Nalls, Mike A. Leveille, Etienne Ruskey, Jennifer A. Jonvik, Hallgeir Tan, Manuela M.X. Bandres-Ciga, Sara Hassin-Baer, Sharon Brockmann, Kathrin Infante, Jon Tolosa, Eduardo Ezquerra, Mario Ben Romdhan, Sawssan Benmahdjoub, Mustapha Arezki, Mohamed Mhiri, Chokri Hardy, John Singleton, Andrew B. Alcalay, Roy N. Gasser, Thomas Grosset, Donald G. Williams, Nigel M. Pittman, Alan Gan-Or, Ziv Fernandez-Santiago, Ruben Brice, Alexis Lesage, Suzanne Farrer, Matthew Wood, Nicholas Morris, Huw R. |
author_sort | Brown, Emmeline E. |
collection | PubMed |
description | The LRRK2 gene has rare (p.G2019S) and common risk variants for Parkinson’s disease (PD). DNM3 has previously been reported as a genetic modifier of the age at onset in PD patients carrying the LRRK2 p.G2019S mutation. We analyzed this effect in a new cohort of LRRK2 p.G2019S heterozygotes (n = 724) and meta-analyzed our data with previously published data (n = 754). VAMP4 is in close proximity to DNM3, and was associated with PD in a recent study, so it is possible that variants in this gene may be important. We also analyzed the effect of VAMP4 rs11578699 on LRRK2 penetrance. Our analysis of DNM3 in previously unpublished data does not show an effect on age at onset in LRRK2 p.G2019S carriers; however, the inter-study heterogeneity may indicate ethnic or population-specific effects of DNM3. There was no evidence for linkage disequilibrium between DNM3 and VAMP4. Analysis of sporadic patients stratified by the risk variant LRRK2 rs10878226 indicates a possible interaction between common variation in LRRK2 and VAMP4 in disease risk. |
format | Online Article Text |
id | pubmed-7762821 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-77628212021-01-01 Analysis of DNM3 and VAMP4 as genetic modifiers of LRRK2 Parkinson’s disease Brown, Emmeline E. Blauwendraat, Cornelis Trinh, Joanne Rizig, Mie Nalls, Mike A. Leveille, Etienne Ruskey, Jennifer A. Jonvik, Hallgeir Tan, Manuela M.X. Bandres-Ciga, Sara Hassin-Baer, Sharon Brockmann, Kathrin Infante, Jon Tolosa, Eduardo Ezquerra, Mario Ben Romdhan, Sawssan Benmahdjoub, Mustapha Arezki, Mohamed Mhiri, Chokri Hardy, John Singleton, Andrew B. Alcalay, Roy N. Gasser, Thomas Grosset, Donald G. Williams, Nigel M. Pittman, Alan Gan-Or, Ziv Fernandez-Santiago, Ruben Brice, Alexis Lesage, Suzanne Farrer, Matthew Wood, Nicholas Morris, Huw R. Neurobiol Aging Genetic Reports Abstract The LRRK2 gene has rare (p.G2019S) and common risk variants for Parkinson’s disease (PD). DNM3 has previously been reported as a genetic modifier of the age at onset in PD patients carrying the LRRK2 p.G2019S mutation. We analyzed this effect in a new cohort of LRRK2 p.G2019S heterozygotes (n = 724) and meta-analyzed our data with previously published data (n = 754). VAMP4 is in close proximity to DNM3, and was associated with PD in a recent study, so it is possible that variants in this gene may be important. We also analyzed the effect of VAMP4 rs11578699 on LRRK2 penetrance. Our analysis of DNM3 in previously unpublished data does not show an effect on age at onset in LRRK2 p.G2019S carriers; however, the inter-study heterogeneity may indicate ethnic or population-specific effects of DNM3. There was no evidence for linkage disequilibrium between DNM3 and VAMP4. Analysis of sporadic patients stratified by the risk variant LRRK2 rs10878226 indicates a possible interaction between common variation in LRRK2 and VAMP4 in disease risk. Elsevier 2021-01 /pmc/articles/PMC7762821/ /pubmed/32873436 http://dx.doi.org/10.1016/j.neurobiolaging.2020.07.002 Text en © 2020 The Authors http://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Genetic Reports Abstract Brown, Emmeline E. Blauwendraat, Cornelis Trinh, Joanne Rizig, Mie Nalls, Mike A. Leveille, Etienne Ruskey, Jennifer A. Jonvik, Hallgeir Tan, Manuela M.X. Bandres-Ciga, Sara Hassin-Baer, Sharon Brockmann, Kathrin Infante, Jon Tolosa, Eduardo Ezquerra, Mario Ben Romdhan, Sawssan Benmahdjoub, Mustapha Arezki, Mohamed Mhiri, Chokri Hardy, John Singleton, Andrew B. Alcalay, Roy N. Gasser, Thomas Grosset, Donald G. Williams, Nigel M. Pittman, Alan Gan-Or, Ziv Fernandez-Santiago, Ruben Brice, Alexis Lesage, Suzanne Farrer, Matthew Wood, Nicholas Morris, Huw R. Analysis of DNM3 and VAMP4 as genetic modifiers of LRRK2 Parkinson’s disease |
title | Analysis of DNM3 and VAMP4 as genetic modifiers of LRRK2 Parkinson’s disease |
title_full | Analysis of DNM3 and VAMP4 as genetic modifiers of LRRK2 Parkinson’s disease |
title_fullStr | Analysis of DNM3 and VAMP4 as genetic modifiers of LRRK2 Parkinson’s disease |
title_full_unstemmed | Analysis of DNM3 and VAMP4 as genetic modifiers of LRRK2 Parkinson’s disease |
title_short | Analysis of DNM3 and VAMP4 as genetic modifiers of LRRK2 Parkinson’s disease |
title_sort | analysis of dnm3 and vamp4 as genetic modifiers of lrrk2 parkinson’s disease |
topic | Genetic Reports Abstract |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7762821/ https://www.ncbi.nlm.nih.gov/pubmed/32873436 http://dx.doi.org/10.1016/j.neurobiolaging.2020.07.002 |
work_keys_str_mv | AT brownemmelinee analysisofdnm3andvamp4asgeneticmodifiersoflrrk2parkinsonsdisease AT blauwendraatcornelis analysisofdnm3andvamp4asgeneticmodifiersoflrrk2parkinsonsdisease AT trinhjoanne analysisofdnm3andvamp4asgeneticmodifiersoflrrk2parkinsonsdisease AT rizigmie analysisofdnm3andvamp4asgeneticmodifiersoflrrk2parkinsonsdisease AT nallsmikea analysisofdnm3andvamp4asgeneticmodifiersoflrrk2parkinsonsdisease AT leveilleetienne analysisofdnm3andvamp4asgeneticmodifiersoflrrk2parkinsonsdisease AT ruskeyjennifera analysisofdnm3andvamp4asgeneticmodifiersoflrrk2parkinsonsdisease AT jonvikhallgeir analysisofdnm3andvamp4asgeneticmodifiersoflrrk2parkinsonsdisease AT tanmanuelamx analysisofdnm3andvamp4asgeneticmodifiersoflrrk2parkinsonsdisease AT bandrescigasara analysisofdnm3andvamp4asgeneticmodifiersoflrrk2parkinsonsdisease AT hassinbaersharon analysisofdnm3andvamp4asgeneticmodifiersoflrrk2parkinsonsdisease AT brockmannkathrin analysisofdnm3andvamp4asgeneticmodifiersoflrrk2parkinsonsdisease AT infantejon analysisofdnm3andvamp4asgeneticmodifiersoflrrk2parkinsonsdisease AT tolosaeduardo analysisofdnm3andvamp4asgeneticmodifiersoflrrk2parkinsonsdisease AT ezquerramario analysisofdnm3andvamp4asgeneticmodifiersoflrrk2parkinsonsdisease AT benromdhansawssan analysisofdnm3andvamp4asgeneticmodifiersoflrrk2parkinsonsdisease AT benmahdjoubmustapha analysisofdnm3andvamp4asgeneticmodifiersoflrrk2parkinsonsdisease AT arezkimohamed analysisofdnm3andvamp4asgeneticmodifiersoflrrk2parkinsonsdisease AT mhirichokri analysisofdnm3andvamp4asgeneticmodifiersoflrrk2parkinsonsdisease AT hardyjohn analysisofdnm3andvamp4asgeneticmodifiersoflrrk2parkinsonsdisease AT singletonandrewb analysisofdnm3andvamp4asgeneticmodifiersoflrrk2parkinsonsdisease AT alcalayroyn analysisofdnm3andvamp4asgeneticmodifiersoflrrk2parkinsonsdisease AT gasserthomas analysisofdnm3andvamp4asgeneticmodifiersoflrrk2parkinsonsdisease AT grossetdonaldg analysisofdnm3andvamp4asgeneticmodifiersoflrrk2parkinsonsdisease AT williamsnigelm analysisofdnm3andvamp4asgeneticmodifiersoflrrk2parkinsonsdisease AT pittmanalan analysisofdnm3andvamp4asgeneticmodifiersoflrrk2parkinsonsdisease AT ganorziv analysisofdnm3andvamp4asgeneticmodifiersoflrrk2parkinsonsdisease AT fernandezsantiagoruben analysisofdnm3andvamp4asgeneticmodifiersoflrrk2parkinsonsdisease AT bricealexis analysisofdnm3andvamp4asgeneticmodifiersoflrrk2parkinsonsdisease AT lesagesuzanne analysisofdnm3andvamp4asgeneticmodifiersoflrrk2parkinsonsdisease AT farrermatthew analysisofdnm3andvamp4asgeneticmodifiersoflrrk2parkinsonsdisease AT woodnicholas analysisofdnm3andvamp4asgeneticmodifiersoflrrk2parkinsonsdisease AT morrishuwr analysisofdnm3andvamp4asgeneticmodifiersoflrrk2parkinsonsdisease AT analysisofdnm3andvamp4asgeneticmodifiersoflrrk2parkinsonsdisease |